ESTRO 2024 - Abstract Book

S442

Clinical - Biomarkers

ESTRO 2024

The CD8 radiomic score appeared to be particularly interesting among patients with liver metastases to differentiate between hot and cold liver lesions. While “cold” liver lesions were associated with a worse prognosis, these results, although exploratory, suggest that these lesions could be a new target for optimizing ablative radiotherapy combined with immunotherapy to improve patient survival.

Keywords: immunotherapy, radiomics, radiotherapy

References:

1. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, et al. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol [Internet]. 2020 [cité 11 mars 2023];10. Disponible sur : https://www.frontiersin.org/articles/10.3389/fonc.2020.546604

2. Xie M, Li N, Xu X, Xu Y, Li H, Zhu L, et al. The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study. Cancers. 5 sept 2022;14(17):4333.

3. Lindblad KE, Lujambio A. Liver metastases inhibit immunotherapy efficacy. Nat Med. janv 2021;27(1):25-7.

4. Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. janv 2021;27(1):152-64.

5. Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. sept 2018;19(9):1180-91. 6. Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, et al. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J Immunother Cancer. nov 2020;8(2):e001429. 7. Sun R, Lerousseau M, Briend-Diop J, Routier E, Roy S, Henry T, et al. Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. J Immunother Cancer. oct 2022;10(10):e004867.

3150

Digital Poster

Biological correlates of radiomic biomarkers in malignant melanoma treated with immunotherapy

Maiwand Ahmadsei* 1 , Hubert S. Gabryś* 1,2 , Stephanie Tanadini-Lang 1 , Reinhard Dummer 3 , Mitchell P. Levesque* 3 , Matthias Guckenberger* 1 1 University Hospital Zurich, Department of Radiation Oncology, Zurich, Switzerland. 2 University Hospital Bern, Department of Radiation Oncology, Bern, Switzerland. 3 University Hospital Zurich, Department of Dermatology, Zurich, Switzerland